Literature DB >> 16699033

Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Anja Krause1, Ju H Joh, Neil R Hackett, Peter W Roelvink, Joseph T Bruder, Thomas J Wickham, Imre Kovesdi, Ronald G Crystal, Stefan Worgall.   

Abstract

On the basis of the concept that the capsid proteins of adenovirus (Ad) gene transfer vectors can be genetically manipulated to enhance the immunogenicity of Ad-based vaccines, the present study compared the antiantigen immunogenicity of Ad vectors with a common epitope of the hemagglutinin (HA) protein of the influenza A virus incorporated into the outer Ad capsid protein hexon, penton base, fiber knob, or protein IX. Incorporation of the same epitope into the different capsid proteins provided insights into the correlation between epitope position and antiepitope immunity. Following immunization of three different strains of mice (C57BL/6, BALB/c, and CBA) with either an equal number of Ad particles (resulting in a different total HA copy number) or different Ad particle numbers (to achieve the same HA copy number), the highest primary (immunoglobulin M [IgM]) and secondary (IgG) anti-HA humoral and cellular CD4 gamma interferon and interleukin-4 responses against HA were always achieved with the Ad vector carrying the HA epitope in fiber knob. These observations suggest that the immune response against an epitope inserted into Ad capsid proteins is not necessarily dependent on the capsid protein number and imply that the choice of incorporation site in Ad capsid proteins in their use as vaccines needs to be compared in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699033      PMCID: PMC1472137          DOI: 10.1128/JVI.02667-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

Review 1.  Genetic targeting strategies for adenovirus.

Authors:  Sam C Noureddini; David T Curiel
Journal:  Mol Pharm       Date:  2005 Sep-Oct       Impact factor: 4.939

2.  Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment.

Authors:  T J Wickham; P Mathias; D A Cheresh; G R Nemerow
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

3.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

4.  Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo.

Authors:  M A Rosenfeld; W Siegfried; K Yoshimura; K Yoneyama; M Fukayama; L E Stier; P K Pääkkö; P Gilardi; L D Stratford-Perricaudet; M Perricaudet
Journal:  Science       Date:  1991-04-19       Impact factor: 47.728

5.  Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms.

Authors:  C Wohlfart
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

6.  Specific antibodies modulate the interactions of adenovirus type 5 with dendritic cells.

Authors:  S Mercier; H Rouard; M H Delfau-Larue; M Eloit
Journal:  Virology       Date:  2004-05-01       Impact factor: 3.616

7.  Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector.

Authors:  J Hersh; R G Crystal; B Bewig
Journal:  Gene Ther       Date:  1995-03       Impact factor: 5.250

8.  Expression of a foreign epitope on the surface of the adenovirus hexon.

Authors:  J Crompton; C I Toogood; N Wallis; R T Hay
Journal:  J Gen Virol       Date:  1994-01       Impact factor: 3.891

9.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Authors:  M A Rosenfeld; K Yoshimura; B C Trapnell; K Yoneyama; E R Rosenthal; W Dalemans; M Fukayama; J Bargon; L E Stier; L Stratford-Perricaudet
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

10.  Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay.

Authors:  B D Plikaytis; S H Turner; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

View more
  37 in total

1.  A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.

Authors:  Kasey A Karen; Cailin Deal; Robert J Adams; Carolyn Nielsen; Cameron Ward; Diego A Espinosa; Jane Xie; Fidel Zavala; Gary Ketner
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Structural variations in species B adenovirus fibers impact CD46 association.

Authors:  Lars Pache; Sangita Venkataraman; Vijay S Reddy; Glen R Nemerow
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

Review 3.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

4.  PhiXing-it, displaying foreign peptides on bacteriophage ΦX174.

Authors:  Kristofer J Christakos; Janice A Chapman; Bentley A Fane; Samuel K Campos
Journal:  Virology       Date:  2015-12-03       Impact factor: 3.616

5.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

6.  The effect of fiber truncations on the stability of adenovirus type 5.

Authors:  Grit Kupgan; Danielle C Hentges; Nathan J Muschinske; William D Picking; Wendy L Picking; Joshua D Ramsey
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

7.  Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.

Authors:  Dongming Zhou; Te-Lang Wu; Kristel L Emmer; Raj Kurupati; Steven Tuyishime; Yan Li; Wynetta Giles-Davis; Xiangyang Zhou; Zhiquan Xiang; Qin Liu; Sarah J Ratcliffe; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

8.  Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.

Authors:  Linlin Gu; Anitra L Farrow; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  J Vis Exp       Date:  2015-05-06       Impact factor: 1.355

Review 9.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

Review 10.  The march toward malaria vaccines.

Authors:  Stephen L Hoffman; Johan Vekemans; Thomas L Richie; Patrick E Duffy
Journal:  Vaccine       Date:  2015-08-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.